With this new joint effort, Syzygy is one step closer to commercial scale of its decarbonization technology. Photo courtesy of Syzygy

A Houston tech company has joined forces with a nonprofit to test a new sustainable fuel production process.

The project is a joint effort from Houston-based Syzygy Plasmonics and nonprofit research institute RTI International and sponsored by Equinor Ventures and Sumitomo Corporation of Americas. Based in the RTI facility in Research Triangle Park, North Carolina, the six-month pilot is testing a way to convert two potent greenhouse gases — carbon dioxide (CO2) and methane (CH4) — into low-carbon-intensity fuels, which have the potential to replace petroleum-based jet fuel, diesel, and gasoline.

"This demonstration will be the first of its kind and represents a disruptive step in carbon utilization. The sustainable fuels produced are expected to quickly achieve cost parity with today's fossil fuels," says Syzygy CEO Trevor Best in a news release. "Integrating our technology with RTI's Fischer-Tropsch synthesis system has the potential to significantly reduce the carbon intensity of shipping, trucking, and aviation without requiring major fleet modifications."

According to Syzygy, the pilot is a step toward being able to scale the process to a commercial-ready Syzygy e-fuels plant.

"By making minor adjustments in the process, we also expect to produce sustainable methanol using the same technology," Best continues.

An independent research institute, RTI International's focus is on improving the human condition. The multidisciplinary nonprofit seeks to support science-based solutions like Syzygy's technology, which has already proven its scale-up capabilities in earlier testing.

Through the partnership, RTI will assist Syzygy with process design and systems integration for the pilot-scale demonstration. Once it reaches commercial scale, the technology is expected to turn millions of tons of CO2 per year to produce sustainable fuels.

"We are excited about the opportunity to collaborate with Syzygy to test and assist in the scale-up of this promising technology," says Sameer Parvathikar, Ph.D., the director of the Renewable Energy and Energy Storage program in RTI's Technology Advancement and Commercialization business unit. "This work aligns with our capabilities, our goals of helping de-risk and commercialize novel technologies, and our vision to address the world's most critical problems with science-based solutions."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston femtech co. debuts new lactation and wellness pods

mom pod

Houston-based femtech company Work&, previously known as Work&Mother, has introduced new products in recent months aimed at supporting working mothers and the overall health of all employees.

The company's new Lactation Pod and Hybrid Pod serve as dual-use lactation and wellness spaces to meet employer demand, the company shared in a news release. The compact pods offer flexible design options that can serve permanent offices and nearly all commercial spaces.

They feature a fully compliant lactation station while also offering wellness functionalities that can support meditation, mental health, telehealth and prayer. In line with Work&'s other spaces, the pods utilize the Work& scheduling platform, which prioritizes lactation bookings to help employers comply with the PUMP Act.

“This isn’t about perks,” Jules Lairson, Work& co-founder and COO, said in the release. “It’s about meeting people where they are—with dignity and intentional design. That includes the mother returning to work, the employee managing anxiety, and everyone in between.”

According to the company, several Fortune 500 companies are already using the pods, and Work& has plans to grow the products' reach.

Earlier this year, Work& introduced its first employee wellness space at MetroNational’s Memorial City Plazas, representing Work&'s shift to offer an array of holistic health and wellness solutions for landlords and tenants.

The company, founded in 2017 by Lairson and CEO Abbey Donnell, was initially focused on outfitting commercial buildings with lactation accommodations for working parents. While Work& still offers these services through its Work&Mother branch, the addition of its Work&Wellbeing arm allowed the company to also address the broader wellness needs of all employees.

The company rebranded as Work& earlier this year.

Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”